Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SCPX

Scorpius Holdings Inc.

Sep 27 • 04:00PM ET

0.7300

Dollar change +0.0288
Percentage change 4.11	%

Healthcare • Biotechnology • USA • AMEX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-200.40	Insider Own	10.54%	Shs Outstand	3.12M	Perf Week	-9.55%
Market Cap	2.28M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.79M	Perf Month	-11.42%
Income	-31.83M	PEG	-	EPS next Q	-	Inst Own	4.73%	Short Float	0.70%	Perf Quarter	-90.87%
Sales	9.85M	P/S	0.23	EPS this Y	-	Inst Trans	-77.17%	Short Ratio	0.19	Perf Half Y	-97.70%
Book/sh	51.92	P/B	0.01	EPS next Y	-	ROA	-46.61%	Short Interest	0.02M	Perf Year	-99.37%
Cash/sh	0.48	P/C	1.51	EPS next 5Y	-	ROE	-79.55%	52W Range	0.70 - 113.00	Perf YTD	-99.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	22.72%	ROI	-80.81%	52W High	-99.35%	Beta	-0.31
Dividend TTM	-	Quick Ratio	0.31	Sales past 5Y	325.62%	Gross Margin	-23.47%	52W Low	4.29%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	0.32	EPS Y/Y TTM	50.07%	Oper. Margin	-330.27%	RSI (14)	34.61	Volatility	9.85% 10.03%
Employees	84	Debt/Eq	0.62	Sales Y/Y TTM	30.51%	Profit Margin	-323.34%	Recom	1.00	Target Price	1600.00
Option/Short	No / Yes	LT Debt/Eq	0.54	EPS Q/Q	74.71%	Payout	-	Rel Volume	0.15	Prev Close	0.70
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	15.53%	Earnings	Aug 20 BMO	Avg Volume	104.46K	Price	0.73
SMA20	-11.53%	SMA50	-67.19%	SMA200	-97.94%	Trades		Volume	15,305	Change	4.11%

Sep-12-24 08:00AM	Scorpius Holdings Commends the U.S. House of Representatives' Passage of the BIOSECURE Act (GlobeNewswire)
Sep-09-24 08:30AM	Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA (GlobeNewswire)
Aug-26-24 08:00AM	Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, and Path Toward Positive Cash Flow (GlobeNewswire)
Aug-20-24 09:15AM	Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024 (GlobeNewswire) -10.52%
Aug-19-24 01:08PM	Scorpius Holdings, Inc. Announces Closing of Public Offering (GlobeNewswire) -12.84%
09:50AM	Loading…
Aug-16-24 09:50AM	Scorpius Holdings, Inc. Announces Pricing of Public Offering (GlobeNewswire)
Aug-09-24 03:38PM	Scorpius Holdings, Inc. Provides Update on its Previously Announced Public Offering (GlobeNewswire)
Aug-06-24 08:45AM	Scorpius Holdings Weighted-Average Pipeline Surpasses $100 Million in Business Develop Opportunities Across Both Manufacturing Client and Government Sectors (ACCESSWIRE) +19.27%
08:16AM	Exclusive: Healthcare Service Provider Scorpius Surpasses $100M In Business Opportunities, Eyes Revenue Boost (Benzinga)

Scorpius Holdings, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCPX

Scorpius Holdings Inc.

Upgrade your FINVIZ experience